NeoVista®, Inc. Announces Validation of Radiation Source Technology

Share Article

Key Milestone Achieved in Validating Product Design and Function

NeoVista, Inc. (, an ophthalmic medical device company today announced the publication of a seminal study highlighting the accuracy of their radioactive source wires, utilized to treat Wet Age-Related Macular Degeneration (AMD).

"The Company's strategy was to meet the requirements called out in the Nuclear Regulatory Commission's guidelines, specifically 10 CFR 35.432 (Calibration measurements of brachytherapy sources). We are very pleased to state that we accomplished this important objective," stated John N. Hendrick, President and CEO of NeoVista, Inc. "This will certainly give further credence to the design and function of our first commercial product, the VIDION® Anti-NeoVascular Therapy System."

NeoVista initiated the study of utilizing a (Standard Imaging) Well Chamber to meet all requirements under the NRC's guidelines found in 10 CFR 35.432. This required the specific design of a holding fixture and collimator for the VIDION device. This activity took over one year of development. Publication of the article, "Investigation of a 90Sr/90Y source for intra-ocular treatment of wet age-related macular degeneration" in the journal Medical Physics (scheduled for October 2009 publication) authored by the Medical Radiation Research Center at the University of Wisconsin-Madison, establishes the mechanism by which each source being utilized is directly traceable to NIST (National Institutes of Standards and Technology) absorbed dose to water standards. This work meets the medical physics requirements of having independent calibration laboratories verify methodology and calibration.

About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Fremont, California. The company's first commercial product, the VIDION® ANV® Therapy System, is cleared for commercial sale in all markets that accept a CE Mark. NeoVista, Inc is hoping to begin commercial activity in the US in early 2011. For more information about the company, or this novel neovascular AMD therapy, please visit the company's Web site at

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tony Moses
Visit website